Department of Surgery
Chief, Section of Pediatric Surgery
Jessica Kandel is an expert in pediatric surgery. She specializes in the treatment of pediatric cancers, including Wilms tumor, neuroblastoma, and hepatoblastoma, as well as vascular anomalies (hemangiomas, venous malformations, lymphatic malformations). Her research focuses on the development and differentiation of blood vessels (angiogenesis) in solid tumors and vascular anomalies. She was a leader in early studies that suppressed tumor growth by blocking vascular endothelial growth factor, a protein that stimulates angiogenesis. Her work contributed to the development of bevacizumab, a drug used to manage metastatic colorectal, lung, and kidney cancers. As the primary investigator on several long-term studies, Kandel’s current goal is to understand how tumors become resistant to therapies, in order to identify new treatments for refractory cancers.
Kandel has contributed widely to medical literature, publishing more than 60 peer-reviewed articles and three book chapters on angiogenesis and tumor growth. She currently serves as an editor for Oncology Letters and as a reviewer for several other scientific journals.
Following her receipt of a BA in medieval studies from Yale University, Kandel received her MD from Columbia University. She completed her internship and residency training in general surgery at Massachusetts General Hospital, as well as fellowship training in research at the Pediatric Surgical Research Laboratories at Boston Children’s Hospital and in pediatric surgery at The Johns Hopkins Hospital.
Kandel joined the University of Chicago faculty in 2013.